(No) Change at Novation
Executive Summary
A new president for this leading hospital group, but no change is anticipated.
You may also be interested in...
The Next Big Thing In Gene Therapy Might Not Be Gene Therapy
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead Sees Room For Trodelvy In European Markets
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.